The study was done to determine the effect of dietary supplementation with 1% non-digestible scFOS/lcFOS on the safety and efficacy of SCIT using a peanut allergy mouse model.
Mice received a scFOS/lcFOS for the rest of the study. Mice were dosed with a single subcutaneous injection of PE or PBS. Mice were dosed subcutaneously with PE or PBS for 3 weeks. Hereafter, acute allergic skin responses, anaphylactic shock symptoms, and body temperature were assessed. To study the mechanism in vitro, the human IgE receptor (FcεRI)-transfected RBL the line was sensitized with an oligoclonal pool of (chu)IgE antibodies against BLG and incubated with the oligosaccharides before exposure to BLG to assess direct the effect on degranulation.
scFOS/lcFOS reduced anaphylaxis caused by a single PE SCIT dose. scFOS/lcFOS alone also reduced the acute allergic skin response. Dietary supplementation with scFOS/lcFOS did not improve the efficacy of SCIT.
The study concluded through its findings that the scFOS/lcFOS diet improves the safety of SCIT, as evidenced by lower anaphylactic responses without compromising the efficacy in a mouse model for peanut allergy.
Reference: https://clinicalmolecularallergy.biomedcentral.com/articles/10.1186/s12948-019-0111-5
